会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明授权
    • Hydroxyl-containing bicyclic compounds
    • 含羟基的双环化合物
    • US6133274A
    • 2000-10-17
    • US756703
    • 1996-11-26
    • Gail E. UnderinerDavid PorubekJ. Peter KleinPaul Woodson
    • Gail E. UnderinerDavid PorubekJ. Peter KleinPaul Woodson
    • A61K31/519A61K31/522C07D473/04A61K31/52
    • A61K31/522A61K31/519
    • Disclosed are therapeutic compounds having the formula:(R)j-(core moiety),including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.
    • 公开了具有下式的治疗化合物:(R)j-(核心部分),包括拆分的对映异构体,非对映体,水合物,盐,溶剂合物及其混合物。 j是1至3的整数,核心部分是非环状的或包含至少一个五至七元环结构,R可以选自氢,卤素,羟基,氨基,取代或 未取代的苄基,C 1-6烷基或C 1-6烯基,并且至少一个R具有式I:n是7至20的整数,X或Y中的至少一个是-OH。 不是-OH的X或Y中的另一个是氢,CH 3 - ,CH 3 -CH 2 - ,CH 3 - (CH 2)2 - 或(CH 3)2 -CH 2 - ,并且每个W 1,W 2和W 3独立地 氢,CH 3 - ,CH 3 -CH 2 - ,CH 3 - (CH 2)2 - 或(CH 3)2 -CH 2 - 。 X,Y,W1,W2或W3烷基可以是未取代的或被羟基,卤素或二甲基氨基取代。 所公开的化合物及其治疗组合物可用于治疗由第二信使活性介导的患有疾病或治疗诱导的毒性的个体。